Vaughn Bryan T, the Executive Vice President and President of Diagnostics at LabCorp, recently sold 306 shares of common stock on November 3, 2026. This transaction is significant as it highlights the ongoing activity and strategic decisions within LabCorp, a prominent player in the medical laboratories sector.

Background

LabCorp Holdings Inc., identified by the Central Index Key (CIK) 0000920148, operates in the medical laboratories industry, classified under the Standard Industrial Classification (SIC) code 8071. The company is headquartered in Burlington, North Carolina, and has undergone several name changes in its history, including its former name, Laboratory Corp of America Holdings. Recent filings indicate a consistent pattern of stock transactions by key executives.

What the Filing Says

According to the SEC filing with accession number 0000920148-26-000228, Vaughn Bryan T executed a sale of 306 shares at a price of $353.70 each. Following this transaction, he retains ownership of approximately 6,844.91 shares of LabCorp stock. The filing notes that this transaction was made pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.

Impact

This sale may impact LabCorp's internal dynamics and investor perceptions. As a key executive, Vaughn Bryan T's actions are closely monitored by stakeholders and can influence the company's stock performance and strategic direction. The medical laboratories sector continues to evolve, and such transactions are indicative of the ongoing adjustments within the industry.

What's Next

The filing does not say what happens next.